CureOs® BONE GRAFT

CureOs® bone graft is a synthetic bone graft manufactured by Linacol Company located in Hacettepe Technopolis campus in Ankara-Turkey. SCIDEUS company have been proudly authorized as the official facilitator  for the foreign trade of Linacol Company's products.
 

Linacol Medikal Company

Linacol is an active R&D and industrial company that is founded in 2007. By using modern laboratories, cleanrooms and genius scientists, Linacol has always been a pioneer in medical researches, developments, and industries since founded.

All products in the Linacol Medical product portfolio have been developed as R&D projects and they have been supported by the Scientific and Technological Research Council of Turkey and Small and Medium Enterprises Development and Support Administration of Turkey.

Linacol Medical production facility is certified by UDEM Certification Company with ISO 13485 certificate and all Linacol Medical products are certified by UDEM with CE certification.

logo.png

What is CureOs® BONE GRAFT ?

CureOs® bone graft is a synthetic graft produced in the modern facilities of Linacol. It consist of over 95 percent of β-Tri Calcium Phosphate plus silicate which gives the best quality resembling real bone structure the highest functionality for the regeneration of bone during the healing process. A good amount of total porosity volume, optimum pore size, great biodegradability value, optimum mechanical stability, ease of use by no pretreatment, and preparing needed and production in variable and different sizes and shapes, makes this product to be one of the best among of its kinds worldwide.

When are CureOs® can be used ?

It can be used for filling all traumatic and pathological bone (Limb, Spine and Pelvis) cavities. It can also be used with other graft materials. Type and volume of graft to be used; is determined by the physician depending on the size and type of the      defect. Also; It is indicated for repair of traumatic bone defects, repair of pathological bone defects, osteosynthesis, treatment of fractures, tibial    osteotomy, all other bone tissue repairs required by the physician.
Also, CureOs® is used to treat bone defects that occur after trauma, bone infections,   congenital anomalies, musculoskeletal tumor surgery, reconstructive procedures such as    revision arthroplasty surgery, and spinal surgery.

Cellular Molecular Physiopathology

After implanting the product to the body due to its special chemical structure, surface area, pore size, and porosity an inflammatory process similar to what we see in the early period of fracture healing will be initiated.

It is assumed that the first cells that interact with artificial bone tissue are monocytes, causing the release of interleukin (IL) -1 beta (B), IL-6, and tumor necrosing factor alpha (TNF-a). Later, endothelial cells and neutrophils enter the circuit and cause prostaglandin 2 to intensify on the one hand, and at the other hand to formation of vascular factors. Immediately after bone destruction, fibroblast growth factor (FGF) 2, platelet-derived growth factor (PDGF) and modifying growth factor (TGF) beta are released .  In this way, while the artificial bone tissue is destroyed, it is replaced by new bone tissue. The equilibrium between bone formation and artificial bone tissue destruction may differ in the presence of radiotherapy, systemic diseases such as diabetes, infections, drugs used such as anti-inflammatory or steroids.

The destruction of artificial tissue and its replacement with new bone tissue is happened from outside to inside and from periphery to central manner. In order to increase the mechanical properties of artificial bone tissue, which exemplifies the intercellular network, silicon in form of silicate have been used on this product which has been already proven its positive role by lots of studies around the world.

(Korkusuz P, Korkusuz F. Hard tissue-biomaterial interactions. In: Yaszemski MJ, Trantolo DJ, Lewandrowski KU, Hasırcı V, Altobelli DE, Wise DL, editors. Biomaterials in orthopedics. New York: Marcel Dekker; 2004. p. 1-40), ( Vakıfahmetoğlu Ç, Park J, Korkusuz F, Öztürk A, Timuçin M. Production and properties of apatite-wollastonite ceramics for biomedical applications. In: Ravaglioli A, Krajewski A, editors. Ceramics, cells and tissues: nanotechnology for functional repair and regenerative medicine. Rome: Consiglio Nazionale Delle Ricerche; 2008. p. 242-51).

CureOs® clinical study

Is there any negative feedback ?

In line with the After Sales Surveillance Procedure, there is no negative feedback after placing on the market until now.

Shapes, Packaging, Sizes

For Getting a Quote please fill the form and submit

Thanks for submitting! We will back you soon!